The novel atypical antipsychotics
| Intervention | Outcomes | ||||
|---|---|---|---|---|---|
| Experimental | Control | Immediate | Short term (0–6 weeks) | Medium term (7 weeks—6 months) | Long term (>6 months) |
| RR = Relative risk—the experimental event rate/control event rate; CI = 95% confidence intervals—an estimate of the precision of RR; ⇓ = decreased; ⇑ = increased; ⇔ = no clear difference. | |||||
| Amisulpride41 | Typical antipsychotics | Improved ⇑ (RR=1.2; CI 1.06 to 1.4) | |||
| 415 participants | 219 participants | Attrition ⇓ (RR=0.7; CI 0.5 to 0.9) | |||
| Movement disorders ⇓ (RR=0.5; CI 0.3 to 0.6) | |||||
| Olanzapine35 | Typical antipsychotics | Improved ⇑ (RR=1.5; CI 1.3 to 1.7) | Relapse ⇔ (RR=0.9; CI 0.8 to 1.0) | ||
| 2049 participants | 925 participants | Attrition ⇓ (RR=0.7; CI 0.6 to 0.8) | Attrition ⇓ (RR=0.9; CI 0.8 to 0.93) | ||
| Movement disorders ⇓ (RR=0.3; CI 0.2 to 0.4) Sedation ⇓ (RR=0.8; CI 0.7 to 0.9) | |||||
| Olanzapine35 | Risperidone | Improved ⇔ (RR=1.2; CI 1 to 1.5) | Attrition ⇓ (RR=0.8; CI: 0.6–0.9) | Attrition ⇔ (RR=0.6; CI 0.4 to 1.2) | |
| 193 participants | 188 participants | Attrition ⇔ (RR=0.8; CI 0.6 to 1.2) Movement disorders ⇓ (RR=0.6; CI 0.4 to 0.9) | |||
| Quetiapine42 | Typical antipsychotics | Improved ⇔ (RR=0.9; CI 0.7 to 1.2) | |||
| 580 participants | 379 participants | Attrition ⇔ (RR=1; CI 0.9 to 1.1) | |||
| Movement disorders ⇓ (RR=0.3; CI 0.2 to 0.4) | |||||
| Sedation ⇑ (RR=1.5; CI 1.1 to 2.2) | |||||
| Risperidone38 | Typical antipsychotics | Improved ⇑ (RR=1.3; CI 1.1 to 2) | |||
| 2299 participants | 1113 participants | Attrition ⇓ (RR=0.8; CI 0.7 to 0.9) Movement disorders ⇓ (RR=0.6; CI 0.5 to 0.7) Sedation ⇓ (RR=0.9; CI 0.8 to 0.99) Weight ⇑ (RR=1.4; CI 1.1 to 1.7) | |||
| Zotepine47 | Typical antipsychotics | Improved ⇑ (RR=1.4; CI 1.1 to 1.8) | |||
| 269 participants | 268 participants | Attrition ⇔ (RR=0.8; CI 0.6 to 1) | |||
| Movement disorders ⇓ (RR=0.7; CI 0.5 to 0.8) | |||||
| Sedation ⇔ (RR=1.6; CI 0.7 to 3) | |||||
| Zotepine47 | Clozapine, risperidone | Attrition ⇔ (RR=1.4; CI 0.7 to 3) | |||
| 55 participants | 55 participants | Movement disorders ⇑ (RR=2.8; CI 1.2 to 7) | |||
| Ziprasidone46 | Typical antipsychotics | Attrition ⇔ (RR=0.9; CI: 0.7–1.4) | Improved ⇔ (RR=0.7; CI 0.5 to 1.01) | ||
| 517 participants | 312 participants | Movement disorders ⇓ (RR=0.34; CI: 0.2–0.6) | Attrition ⇔ (RR=1.1; CI 0.7 to 1.6) | ||
| Movement disorders ⇓ (RR=0.4; CI 0.2 to 0.6) Sedation ⇔ (RR=1.6; CI: 0.7–3) | |||||